WCG has acquired VeraSci, a global provider of specialty scientific expertise and eClinical software to support clinical trials focused on central nervous system (CNS) disorders. VeraSci, based in Durham, NC, expands WCG’s scientific and patient engagement capabilities, and complements its CNS offerings, including those available via the Company’s MedAvante, ProPhase and Analgesic Solutions businesses. With this acquisition, WCG aims to address the growing demand for scientific and technology solutions for remote data capture, hybrid virtual studies and fully decentralized clinical trials in key CNS therapeutic areas.
 
VeraSci provides clients with innovative solutions that aim to improve data quality in clinical trials, including endpoint and assessment services, rater training and certification, language and translation support, and eCOA and ePRO technologies. With its Pathway technology platform, which can be configured to meet the needs of any study across the globe, VeraSci is designed to enable the collection of high-quality data that can be used to assess symptoms, cognition and functional capacity in a wide range of therapeutic indications.

“WCG’s acquisition of VeraSci represents a natural next step and an exciting growth opportunity,” said Donald A. Deieso, Ph.D., Executive Chairman and CEO of WCG. “On behalf of WCG, I’m proud to welcome VeraSci, an organization that shares our dedication to improving the clinical trial experience for patients and sites, commitment to scientific rigor and passion for bringing novel technologies into clinical trial processes. This is a marriage of two premier global teams with a common vision.”